Brief: Pharnext confirms support for Hereditary Neuropathy Foundation
15/09/2016 07:01
Sept 15 (Reuters) - Pharnext SAS PHARN.PA :
* Pharnext confirms its continuous support of the Hereditary Neuropathy Foundation to
increase global awareness of Charcot-Marie-Tooth (CMT) disease
* "We continue to advance development of PXT3003, currently in an international phase 3
trial, for treatment of patients with CMT type 1A"
Source text for Eikon: ID:nBw2Y2J63a
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development